Bolt Biotherapeutics (BOLT) EPS (Weighted Average and Diluted) (2021 - 2025)
Bolt Biotherapeutics (BOLT) has disclosed EPS (Weighted Average and Diluted) for 5 consecutive years, with -$3.91 as the latest value for Q4 2025.
- Quarterly EPS (Weighted Average and Diluted) rose 53.06% to -$3.91 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$12.38 through Dec 2025, up 55.24% year-over-year, with the annual reading at -$17.85 for FY2025, 46.01% up from the prior year.
- EPS (Weighted Average and Diluted) hit -$3.91 in Q4 2025 for Bolt Biotherapeutics, down from -$3.72 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.28 in Q1 2024 to a low of -$11.12 in Q2 2024.
- Historically, EPS (Weighted Average and Diluted) has averaged -$2.53 across 5 years, with a median of -$0.62 in 2021.
- Biggest five-year swings in EPS (Weighted Average and Diluted): plummeted 2216.67% in 2024 and later soared 59.89% in 2025.
- Year by year, EPS (Weighted Average and Diluted) stood at -$0.73 in 2021, then grew by 27.4% to -$0.53 in 2022, then increased by 11.32% to -$0.47 in 2023, then plummeted by 1672.34% to -$8.33 in 2024, then skyrocketed by 53.06% to -$3.91 in 2025.
- Business Quant data shows EPS (Weighted Average and Diluted) for BOLT at -$3.91 in Q4 2025, -$3.72 in Q3 2025, and -$4.46 in Q2 2025.